Abstract
Early empiric antibiotic therapy can significantly decrease the risk of mortality and infectious morbidity in patients with hematologic malignancies. Broad-spectrum antibiotics, usually a combination regimen of a beta-lactam and an aminoglycoside, have traditionally been employed against the wide variety of organisms that cause febrile episodes. However, since the 1970's, there has been a shift in epidemiology from Gram-negative to Gram-positive infections, against which traditional combination regimens have only limited efficacy. The carbapenems offer a suitable monotherapeutic alternative as they have a very broad spectrum of antibacterial activity, and equivalent efficacy and safety compared with combination regimes. Trials using imipenem/cilastatin have shown equal efficacy to ceftazidime but neurologic and gastrointestinal toxicity were observed at high doses (1 g 6-hourly). In the largest study to date, meropenem (1 g 8-hourly) provided effective, well tolerated monotherapy for patients with febrile neuropenia, equivalent to a regimen of ceftazidime plus amikacin. It is concluded that meropenem appears to be a realistic option for initial monotherapy in febrile neutropenic patients, providing therapy that is equivalent to...Continue Reading
References
Dec 1, 1992·The Journal of Antimicrobial Chemotherapy·M J LeylandD Bareford
Feb 1, 1992·Archives of Internal Medicine·K V RolstonL Elting
Jan 1, 1991·European Journal of Haematology·P C HuijgensM M Langenhuijsen
Mar 1, 1990·The Journal of Infectious Diseases
Jul 1, 1990·Antimicrobial Agents and Chemotherapy·R LiangD Todd
Feb 1, 1986·Antimicrobial Agents and Chemotherapy·J KlasterskyH Gaya
Aug 28, 1986·The New England Journal of Medicine·P A PizzoJ McKnight
Dec 1, 1972·Antimicrobial Agents and Chemotherapy·J KlasterskyD Daneau
May 13, 1971·The New England Journal of Medicine·S SchimpffA Serpick
Feb 1, 1966·Annals of Internal Medicine·G P BodeyE J Freireich
Jan 1, 1995·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·A G FreifeldR C Young
May 6, 1993·The New England Journal of Medicine·P A Pizzo
Nov 1, 1995·Infection·A BöhmeD Hoelzer
May 1, 1996·Antimicrobial Agents and Chemotherapy·A ComettaM P Glauser
Citations
Nov 24, 1999·International Journal of Antimicrobial Agents·M AkovaE Kansu
Dec 20, 2007·Pediatric Hematology and Oncology·Kamolwish LaoprasopwattanaMalai Wongchanchailert
May 20, 2008·Pediatric Hematology and Oncology·I YildirimS Yetgin
Feb 26, 2000·Pediatric Hematology and Oncology·T BernigH Reddemann
Apr 2, 2002·Expert Opinion on Investigational Drugs·Giovanni BonfiglioGiuseppe Nicoletti
Jun 16, 2011·Pediatric Blood & Cancer·Serap KaramanRejin Kebudi
Sep 12, 2009·Pediatrics International : Official Journal of the Japan Pediatric Society·Sema VuralRejin Kebudi
Mar 17, 1999·Journal of Chemotherapy·E CastagnolaG Dini
Jul 19, 2003·Journal of Chemotherapy·R FanciG Longo
Aug 5, 2008·Journal of Chemotherapy·R FanciA Bosi
Apr 30, 2010·Japanese Journal of Clinical Oncology·Nefise OztoprakHandan Ankarali
Sep 17, 2009·British Journal of Cancer·D Cameron
Nov 12, 2010·The Cochrane Database of Systematic Reviews·Mical PaulLeonard Leibovici
Aug 28, 2002·The Annals of Pharmacotherapy·Wendelin K NelsonRoger H Giller